Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

29.73USD
11:08am EDT
Change (% chg)

$0.03 (+0.10%)
Prev Close
$29.70
Open
$29.56
Day's High
$30.29
Day's Low
$29.51
Volume
22,496
Avg. Vol
107,577
52-wk High
$34.62
52-wk Low
$18.67

Latest Key Developments (Source: Significant Developments)

Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share
Tuesday, 20 Mar 2018 07:44pm EDT 

March 20 (Reuters) - Xencor Inc ::XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.30 MILLION COMMON SHARES PRICED AT $31.00PER SHARE.  Full Article

Xencor Files For Potential Mixed Shelf Offering
Monday, 19 Mar 2018 05:34pm EDT 

March 19 (Reuters) - Xencor Inc ::XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING ‍​.  Full Article

Xencor Announces Proposed Public Offering Of Common Stock
Monday, 19 Mar 2018 04:09pm EDT 

March 19 (Reuters) - Xencor Inc ::XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.XENCOR INC - INTENDS TO OFFER AND SELL 5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Xencor Reports Q4 Loss Per Share $0.25
Tuesday, 27 Feb 2018 04:01pm EST 

Feb 27 (Reuters) - Xencor Inc ::XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $10.9 MILLION VERSUS $6.4 MILLION.Q4 LOSS PER SHARE $0.25.‍XENCOR EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS BEYOND 2020​.‍EXPECTS TO END 2018 WITH APPROXIMATELY $240 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.  Full Article

Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors
Thursday, 22 Feb 2018 08:00am EST 

Feb 22 (Reuters) - Xencor Inc ::XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS.XENCOR INC SAYS "EXPECTS TO FILE INDS FOR 3 MORE BISPECIFIC ANTIBODIES FOR SOLID TUMORS THIS YEAR".  Full Article

Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Xencor Inc ::XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS.XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018.  Full Article

Xencor posts Q3 loss of $0.33 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Xencor Inc :Xencor reports third quarter 2017 financial results and provides clinical pipeline update.Q3 revenue $7.1 million versus i/b/e/s view $6.3 million.Q3 loss per share $0.33.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Xencor Q2 loss per share $0.15
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Xencor Inc :Xencor reports second quarter 2017 financial results.Q2 revenue $13.3 million versus $66 million.Q2 revenue view $8.2 million -- Thomson Reuters I/B/E/S.Qtrly earnings per share loss $0.15.  Full Article

Xencor's lead drug candidate receives orphan drug designation from FDA
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Xencor Inc :Xencor's lead drug candidate, xmab5871, receives orphan drug designation from fda for treatment of igg4-related disease.  Full Article

Xencor reports Q1 loss per share $0.31
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Xencor Inc :Xencor reports first quarter 2017 financial results.Q1 loss per share $0.31.Q1 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Xencor Inc - Cash, cash equivalents, and marketable securities totaled $392.7 million as of March 31, 2017, compared to $403.5 million on December 31, 2016.Xencor Inc - Expects to have cash to fund research and development programs and operations beyond end of 2020.Xencor Inc - Expects to end 2017 with approximately $340 million in cash, cash equivalents, and marketable securities.Xencor Inc qtrly revenues $4.3 million versus $7.25 million a year ago.  Full Article